Specimen Validity Testing Market Report 2026

The specimen validity testing market size has grown strongly in recent years. It will grow from $4.03 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to growth in workplace drug testing, regulatory mandates for urine testing, rise in substance abuse cases, forensic testing demand, expansion of clinical laboratories.

The specimen validity testing market size is expected to see strong growth in the next few years. It will grow to $5.95 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to oral fluid testing adoption, technological advancements in assay sensitivity, increasing probation and legal testing, expansion of point-of-care solutions, emerging market penetration. Major trends in the forecast period include increased adulterant detection panels, automation of validity testing workflows, integration with lab information systems, rapid testing kits, workplace drug screening expansion.

The rising prevalence of drug abuse is expected to drive the growth of the specimen validity testing market in the coming years. Drug abuse refers to the habitual, excessive, or inappropriate use of legal or illegal substances for non-medical purposes. The increase in drug abuse is influenced by interconnected factors such as opioid dependence, growing mental health challenges, limited access to treatment and support resources, and cultural representations. Specimen validity testing (SVT) methods are designed to detect impurities and compounds by analyzing parameters such as pH, specific gravity, creatinine content, and temperature. For example, according to the Office for National Statistics, a UK-based government agency, in October 2024, England and Wales recorded 5,448 drug poisoning-related deaths in 2023, representing an 11% increase from 4,907 deaths in 2022. Therefore, the rise in drug abuse is driving the growth of the specimen validity testing market.

The increasing healthcare expenditure is also expected to support the growth of the specimen validity testing market. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on the prevention, treatment, and management of health conditions. Spending in healthcare is rising due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, resulting in greater overall healthcare expenditure. Increased healthcare spending supports specimen validity testing by funding advanced technologies, skilled personnel, and improved laboratory infrastructure, enhancing the accuracy and reliability of tests. For instance, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, U.S. healthcare expenditures in 2023 rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditure is fueling the growth of the specimen validity testing market.

In November 2024, SPT Labtech, a UK-based manufacturer and designer of automated laboratory instruments, partnered with ICE Bioscience. The collaboration aims to accelerate drug discovery through advanced drug screening and automation using cutting-edge technologies. By improving assay development and expanding research capabilities, the partnership seeks to drive innovation within the pharmaceutical industry. ICE Bioscience is a China-based provider of drug screening platforms.

Major companies operating in the specimen validity testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Medline Industries Inc., Becton, Dickinson and Company, Laboratory Corporation, Quest Diagnostics Incorporated, Alere Inc., Clinical Reference Laboratory Inc., Precision Diagnostics, ACM Global Laboratories, Millennium Health, Omega Laboratories Inc., Dominion Diagnostics, CannAmm, Sciteck Inc., Starplex Scientific Inc., Vision Diagnostics Inc., Premier Biotech Inc., Alfa Scientific Designs, Express Diagnostics, American Bio Medica Corporation, Titan Biotech Ltd., SureHire, Miraclean Technology Co. Ltd.

North America was the largest region in the specimen validity testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specimen validity testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the specimen validity testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the specimen validity testing market by increasing prices for imported reagents, analyzers, collection devices, and laboratory instruments. Drug screening laboratories, rehabilitation centers, and law enforcement agencies in Asia-Pacific and Europe are most affected due to reliance on international suppliers. These higher costs can slow testing throughput and expansion of point-of-care services. At the same time, tariffs are encouraging local manufacturing of SVT kits and laboratory consumables, strengthening market stability.

The specimen validity testing market research report is one of a series of new reports that provides specimen validity testing market statistics, including specimen validity testing industry global market size, regional shares, competitors with a specimen validity testing market share, detailed specimen validity testing market segments, market trends and opportunities, and any further data you may need to thrive in the specimen validity testing industry. This specimen validity testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Specimen Validity Testing (SVT) is a process used to evaluate the integrity and authenticity of biological specimens, including urine, blood, saliva, or hair samples, collected for drug testing or clinical analysis. SVT assesses parameters such as pH, creatinine levels, specific gravity, and the presence of common masking agents like oxidizing adulterants, nitrites, glutaraldehyde, and pyridinium chlorochromate.

The main products and services in the specimen validity testing market include both products and services. In this context, products refer to items such as assay kits, reagents, calibrators, and disposables used in testing to identify adulteration, dilution, or substitution in urine samples. Testing methods include laboratory testing and rapid or point-of-care testing, and these are utilized by various end users such as drug rehabilitation centers, drug screening laboratories, pain management centers, criminal justice and law enforcement agencies, and others.

The specimen validity testing market includes revenues earned by entities by creatinine testing, pH testing, adulterant testing, and specific gravity measurement and related specimen collection containers, urine test strips, adulterant detection kits, and temperature strips. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.